Sacuva Tablet 49 mg+51 mg is a high-potency fixed-dose combination of Sacubitril 49 mg and Valsartan 51 mg, developed for the management of heart failure with reduced ejection fraction (HFrEF). As an angiotensin receptor-neprilysin inhibitor (ARNI), it combines the benefits of Sacubitril, a neprilysin inhibitor, with Valsartan, an angiotensin II receptor blocker, to provide comprehensive cardiovascular protection.

Sacuva 49 mg+51 mg is typically used for patients who have been titrated up from a lower dose and require enhanced efficacy to control symptoms and improve cardiac function. It helps reduce hospitalizations, prevent disease progression, and improve survival in adults with chronic heart failure. The dual mechanism addresses both neurohormonal overactivation and fluid retention, making it a cornerstone therapy in HFrEF management.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each tablet contains:

• Sacubitril 49 mg

• Valsartan 51 mg

• Excipients: Microcrystalline cellulose, lactose, magnesium stearate, and other standard excipients

Indications

Sacuva Tablet 49 mg+51 mg is indicated for:

• Chronic heart failure with reduced ejection fraction (HFrEF) to reduce morbidity and mortality

• Improvement of symptoms such as shortness of breath, fatigue, and fluid retention

• Reduction in hospitalization rates due to worsening heart failure

• Patients requiring maintenance therapy after titration from lower Sacubitril/Valsartan doses

• Adults at high risk of cardiovascular events, such as myocardial infarction or stroke, associated with HFrEF

Mechanism of Action

Sacuva combines two complementary pharmacological actions:

1. Sacubitril (Neprilysin inhibitor):

   • Inhibits neprilysin, an enzyme that degrades natriuretic peptides

   • Increases levels of atrial and B-type natriuretic peptides, promoting vasodilation, natriuresis, and diuresis

   • Reduces cardiac fibrosis and remodeling, enhancing heart function

2. Valsartan (Angiotensin II receptor blocker):

   • Blocks angiotensin II type 1 receptors, reducing vasoconstriction, aldosterone secretion, and sodium retention

   • Lowers blood pressure and decreases cardiac workload

   • Complements Sacubitril by mitigating neurohormonal activation, which contributes to heart failure progression

Together, Sacubitril and Valsartan improve hemodynamics, reduce fluid overload, and support long-term cardiovascular health.

Dosage and Administration

• Adults: 1 tablet twice daily, or as prescribed by the physician

• Can be taken with or without food

• Ensure a 36-hour washout if transitioning from ACE inhibitors to avoid risk of angioedema

• Monitor blood pressure, kidney function, and serum potassium regularly

• Dose may be titrated based on tolerability and clinical response

Precautions and Warnings

• Not recommended during pregnancy or breastfeeding

• Avoid concomitant use with ACE inhibitors or aliskiren in patients with diabetes or renal impairment

• Monitor for hypotension, hyperkalemia, and renal function deterioration

• Use cautiously in patients with history of angioedema, liver disease, or severe kidney impairment

• Seek immediate medical attention if experiencing swelling of the face, lips, or throat, severe dizziness, or difficulty breathing

Possible Side Effects

Sacuva Tablet 49 mg+51 mg is generally well tolerated. Common side effects may include:

• Dizziness or lightheadedness

• Hypotension (low blood pressure)

• Hyperkalemia (high potassium levels)

• Mild kidney function changes

• Rarely, angioedema

Most side effects are mild, manageable, and reversible under physician supervision.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage Instructions

• Store in a cool, dry place below 30°C

• Protect from light and moisture

• Keep out of reach of children

Conclusion

Sacuva Tablet 49 mg+51 mg (Sacubitril + Valsartan) is a potent ARNI therapy for maintenance treatment of HFrEF. By targeting both cholesterol synthesis and absorption, it significantly improves cardiac function, reduces hospitalization risk, and enhances quality of life for patients with chronic heart failure. Proper monitoring and lifestyle modifications ensure optimal outcomes with this high-efficacy treatment.